Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Investing in Longevity (Nils Regge, Apollo Health Ventures)

Investing in Longevity (Nils Regge, Apollo Health Ventures)

FromTranslating Aging


Investing in Longevity (Nils Regge, Apollo Health Ventures)

FromTranslating Aging

ratings:
Length:
27 minutes
Released:
Sep 14, 2022
Format:
Podcast episode

Description

Joining Chris on the podcast today is Nils Regge, Co-founder and Managing Director of Apollo Health Ventures.  As a social entrepreneur, company creator, and biotech expert, Nils built Apollo Health Ventures in 2016 to help health tech companies develop methods to prevent and reverse the aging process and extend the healthy human life span.  
At Apollo, Nils makes use of his dealmaking skills, business knowledge, and prior experience growing startups to help boost the success of biotech and health companies.  As the general public becomes increasingly interested in longevity and medical advancements continue to take place at rapid rates, Apollo is a leader in funding and fueling efforts to ensure  healthier  and longer human lifespans. At the moment,  things are looking up as there is a lot of excitement  in the industry - however, Regge finds it important to temper that enthusiasm with the right kind of skepticism.   In a field in which any new advancement is seemingly revolutionary, it’s crucial to stay grounded. 
The Finer Details of This Episode: 
Incentive and organizational structures
Filtering for good ideas
Apollo’s portfolio of companies 
Fusing European and American techniques to company building
The heightened need for funding
Bringing drugs into the clinic

Quotes: 
“If you have something that makes you live 10 years, 20 years, longer, healthier, I think it's the biggest market ever.”
“We do company creation, but we also invest in outside companies.”
“Because we are in this for the long run, we want to make investors money, we want to show the investors that this is a good place to invest or a good space to invest. And then ultimately, we want to be able to raise more money from other bigger institutional investors.”
“You want to create an incentive structure and organizational structure that encourages the right kind of skepticism…you almost want to avoid a certain kind of optimism early on.”
“But because of the excitement in the field, and kind of what I think of as the ‘True Believer' phenomenon, I think we are vulnerable to a little bit of hype. And I think that it's a very good idea to bring that down to earth and say, ‘Okay, that's a good idea. Let us figure out the best way to see if it's gonna fail, and do that first.’”
“So first of all, it's about getting a drug to the market, that's the most important thing, and making sure it's safe and that it's working.”
“There's great science here in Europe, right? So I mean, the universities are great, the people are smart. They're just not as entrepreneurial as they are in the US, per se.”
Links: 
Email questions, comments, and feedback to podcast@bioagelabs.com
Translating Aging on Twitter:https://twitter.com/BioAgePodcast ( @bioagepodcast)
BIOAGE Labs Websitehttps://bioagelabs.com/ ( BIOAGELabs.com)
BIOAGE Labs Twitterhttps://twitter.com/bioagelabs?lang=en ( @bioagelabs)
BIOAGE Labshttps://www.linkedin.com/company/bioage-labs/ ( LinkedIn)
Apollo Health Ventures Homepage: https://www.apollo.vc (https://www.apollo.vc) 
Nils Regge on LinkedIn: https://www.linkedin.com/in/nils-regge-62ab7a28/?originalSubdomain=de (nils-regge-62ab7a28) 
Released:
Sep 14, 2022
Format:
Podcast episode

Titles in the series (51)

On Translating Aging, we talk with the worldwide community of researchers, entrepreneurs, and investors who are moving longevity science from the lab to the clinic. We bring you a commanding view of the entire field, in the words of the people and companies who are moving it forward today. The podcast is sponsored by BioAge labs, a clinical-stage biotechnology company developing therapies to extend human healthspan by targeting the molecular causes of aging.